Trials Sponsors Conditions Drugs Pricing

Conditions

Onychomycosis of Toenail

Keywords

OnychomycosisOnychomycosis of ToenailTrichophyton rubrumTrichophyton mentagrophytes

Outcome Measures

Primary Outcomes (1)

Safety and Tolerability
Subjects will be asked about AEs weekly during the evaluation phase and at every follow-up visit; descriptions of AEs will include, at a minimum: date of onset, date ended, severity, seriousness, relationship to the study drug, and outcome.
24 weeks

Study Arms (1)

Trichostatin A

EXPERIMENTAL

Drug: Trichostatin A

Interventions

Trichostatin ADrug

Topical Study Drug

Trichostatin A

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years - 75 Years

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Willingness to provide signed and dated written voluntary informed consent.
Adults with diagnosis of mild-to-severe DLSO/DSO affecting at least one great toenail.

Sponsors & Collaborators

Vanda Pharmaceuticals
Industrylead

Study Sites (5)

Vanda Investigational Site

Fremont, California, 94538, United States

Vanda Investigational Site

Denver, Colorado, 80210, United States

Vanda Investigational Site

New Brighton, Minnesota, 55112, United States

Vanda Investigational Site

Pflugerville, Texas, 78660, United States

Vanda Investigational Site

Forest, Virginia, 24551, United States

MeSH Terms

Conditions

Onychomycosis

Interventions

trichostatin A

Condition Hierarchy (Ancestors)

TineaDermatomycosesMycosesBacterial Infections and MycosesInfectionsSkin Diseases, InfectiousNail DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Study Design

Study Type: interventional
Phase: phase 2
Allocation: NA
Masking: NONE
Purpose: TREATMENT
Intervention Model: SINGLE GROUP
Sponsor Type: INDUSTRY
Responsible Party: SPONSOR

Study Record Dates

First Submitted

June 5, 2025

First Posted

July 15, 2025

Study Start

May 5, 2025

Actual (reported)

Primary Completion

September 2026

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe Onychomycosis

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (1)

Trichostatin A

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (5)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (1)

Trichostatin A

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (5)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations